Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva)-Pipeline Review, H2 2016

Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva)-Pipeline Review, H2 2016


  • Products Id :- GMDHC8910IDB
  • |
  • Pages: 46
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva)-Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Fibrodysplasia Ossificans Progressiva-Pipeline Review, H2 2016, provides an overview of the Fibrodysplasia Ossificans Progressiva (Musculoskeletal Disorders) pipeline landscape.

Fibrodysplasia ossificans progressiva (FOP) is a disorder in which muscle tissue and connective tissue such as tendons and ligaments are gradually replaced by bone (ossified), forming bone outside that constrains movement. Symptoms swellings in fibrous tissue, pain, fever, muscle ossification and restricted movement of joints. Treatment includes surgery and medications to help relieve symptoms of FOP, such as pain and inflammation.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Fibrodysplasia Ossificans Progressiva-Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Fibrodysplasia Ossificans Progressiva (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Fibrodysplasia Ossificans Progressiva (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 2, 4 and 2 respectively.

Fibrodysplasia Ossificans Progressiva (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Fibrodysplasia Ossificans Progressiva (Musculoskeletal Disorders).

The pipeline guide reviews pipeline therapeutics for Fibrodysplasia Ossificans Progressiva (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Fibrodysplasia Ossificans Progressiva (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Fibrodysplasia Ossificans Progressiva (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Fibrodysplasia Ossificans Progressiva (Musculoskeletal Disorders)

Reasons to Buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Fibrodysplasia Ossificans Progressiva (Musculoskeletal Disorders).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Fibrodysplasia Ossificans Progressiva (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) Overview 6

Therapeutics Development 7

Pipeline Products for Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva)-Overview 7

Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva)-Therapeutics under Development by Companies 8

Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva)-Pipeline Products Glance 9

Clinical Stage Products 9

Early Stage Products 10

Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva)-Products under Development by Companies 11

Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva)-Companies Involved in Therapeutics Development 12

Clementia Pharmaceuticals Inc 12

Daiichi Sankyo Company Ltd 13

Heart Metabolics Ltd 14

La Jolla Pharmaceutical Company 15

Oncodesign SA 16

Pfizer Inc 17

Regeneron Pharmaceuticals Inc 18

Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva)-Therapeutics Assessment 19

Assessment by Monotherapy Products 19

Assessment by Target 20

Assessment by Mechanism of Action 22

Assessment by Route of Administration 24

Assessment by Molecule Type 26

Drug Profiles 28

Antibody to Antagonize ALK2 for Fibrodysplasia Ossificans Progressiva-Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

LJPC-6417-Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

palovarotene-Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

perhexiline maleate-Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

REGN-2477-Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

sirolimus-Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

Small Molecule 1 To Inhibit ALK2 for Fibrodysplasia Ossificans Progressiva-Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

Small Molecule 2 To Inhibit ALK2 for Fibrodysplasia Ossificans Progressiva-Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

Small Molecule to Inhibit Activin Receptor-Like Kinase 2 for fibrodysplasia ossificans progressiva-Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

Small Molecule to Inhibit BMP for Cardiovascular, CNS, Oncology and Musculoskeletal Disorders-Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva)-Product Development Milestones 42

Featured News & Press Releases 42

Oct 14, 2016: Clementia Announces Top-line Results from Phase 2 Trial of Palovarotene for Treatment of Patients with Fibrodysplasia Ossificans Progressiva 42

Aug 08, 2016: Clementia Clinical Program: Opportunity for New Adult and Older Adolescent Subjects to Enroll in Palovarotene Study 43

Jun 13, 2016: Clementia Clinical Program: Next Step in Clementia's Clinical Program for Fibrodysplasia Ossificans Progressiva (FOP) 43

Apr 23, 2016: Clementia Pharmaceuticals Joins Global FOP Community in Recognizing Fibrodysplasia Ossificans Progressiva (FOP) Awareness Day 44

Appendix 45

Methodology 45

Coverage 45

Secondary Research 45

Primary Research 45

Expert Panel Validation 45

Contact Us 45

Disclaimer 46

List of Figures

Number of Products under Development for Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva), H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Comparative Analysis by Clinical Stage Development, H2 2016 9

Comparative Analysis by Early Stage Products, H2 2016 10

Assessment by Monotherapy Products, H2 2016 19

Number of Products by Targets, H2 2016 20

Number of Products by Stage and Targets, H2 2016 20

Number of Products by Mechanism of Actions, H2 2016 22

Number of Products by Stage and Mechanism of Actions, H2 2016 22

Number of Products by Routes of Administration, H2 2016 24

Number of Products by Stage and Routes of Administration, H2 2016 24

Number of Products by Molecule Types, H2 2016 26

Number of Products by Stage and Molecule Types, H2 2016 26

List of Tables

Number of Products under Development for Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva), H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Comparative Analysis by Clinical Stage Development, H2 2016 9

Comparative Analysis by Early Stage Development, H2 2016 10

Products under Development by Companies, H2 2016 11

Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva)-Pipeline by Clementia Pharmaceuticals Inc, H2 2016 12

Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva)-Pipeline by Daiichi Sankyo Company Ltd, H2 2016 13

Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva)-Pipeline by Heart Metabolics Ltd, H2 2016 14

Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva)-Pipeline by La Jolla Pharmaceutical Company, H2 2016 15

Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva)-Pipeline by Oncodesign SA, H2 2016 16

Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva)-Pipeline by Pfizer Inc, H2 2016 17

Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva)-Pipeline by Regeneron Pharmaceuticals Inc, H2 2016 18

Assessment by Monotherapy Products, H2 2016 19

Number of Products by Stage and Target, H2 2016 21

Number of Products by Stage and Mechanism of Action, H2 2016 23

Number of Products by Stage and Route of Administration, H2 2016 25

Number of Products by Stage and Molecule Type, H2 2016 27

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Clementia Pharmaceuticals Inc, Daiichi Sankyo Company Ltd, Heart Metabolics Ltd, La Jolla Pharmaceutical Company, Oncodesign SA, Pfizer Inc, Regeneron Pharmaceuticals Inc

Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) Therapeutic Products under Development, Key Players in Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) Therapeutics, Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) Pipeline Overview, Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) Pipeline, Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) Pipeline Assessment

select a license

Single User License
USD 2000 INR 130100
Site License
USD 4000 INR 260200
Corporate User License
USD 6000 INR 390300

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com